LGI Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of LGI Antibodies for studying leucine-rich glioma-inactivated proteins. LGI Antibodies are validated for multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Leucine-rich glioma-inactivated proteins are essential components in neuronal development and synaptic function, influencing vital processes such as cell signaling and communication. Research has shown that leucine-rich glioma-inactivated protein alterations can lead to various neurological disorders, making them important research targets. Understanding the molecular mechanisms of leucine-rich glioma-inactivated proteins can provide valuable insights into potential therapeutic approaches. Investigating the role of leucine-rich glioma-inactivated proteins in neural networks helps advance our knowledge of brain function and development. Ongoing studies continue to reveal new functions and regulatory mechanisms of leucine-rich glioma-inactivated proteins in health and disease. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of leucine-rich glioma-inactivated proteins and their impact on neurological health.